See the latest news and media coverage for Immunity Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Last updated
In short: Immunity Pharma reported positive Phase 2a clinical results for its ALS treatment IPL344 and presented data on reduced neurofilament light levels.
Phase 2a trial results published in Muscle and Nerve show 58-64% slower ALSFRS-R progression, 27% NfL reduction, and improved survival versus controls. IPL344 was safe and well-tolerated.
Treatment was well tolerated with 48% slower ALSFRS-R decline. Benefits suggested in weight gain, respiration, survival. NfL reduction observed.
Phase 2a study shows mean 20% plasma NfL reduction in six participants. Data presented at ALS/MND symposium. Strengthens IPL344 therapy potential.
Disease progression slowed 50% in functional and respiratory endpoints. Favorable safety profile shown. Biomarker confirms Akt pathway activation.
AC Immune SA (NASDAQ:ACIU) announced today that co-founder and Chief Executive Officer Dr. Andrea Pf...
The long-stalled Dunkirk pharmaceutical project is moving ahead with a new lease for ImmunityBio and tighter controls.
Did you buy IBRX securities between January 19, 2026, and March 24, 2026? Affected IBRX Investor Summary Who: ImmunityBio, Inc. (NASDAQ: IBRX) What: Securities...
ImmunityBio, Inc. (NASDAQ:IBRX) was among Jim Cramer’s recent stock calls on Mad Money. Answering a caller’s query about the stock during the recent lightning round...
Track Immunity Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.